What's in SHI Jia's pipeline?

SHI Jia has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with SHI Jia's portfolio?

Top competitors by shared drug class: CSL Behring, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, IRCCS Policlinico S. Donato.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/shi-jia.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

SHI Jia — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SHI Jia pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Prothrombin Complex Concentrate, Human	Prothrombin Complex Concentrate, Human	marketed	Coagulation factor concentrate	Clotting factors II, VII, IX, X (vitamin K-dependent factors)	Hematology / Hemostasis

Therapeutic area mix

Hematology / Hemostasis · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

CSL Behring · 1 shared drug class
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · 1 shared drug class
IRCCS Policlinico S. Donato · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for SHI Jia:

Cite this brief

Drug Landscape (2026). SHI Jia — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/shi-jia. Accessed 2026-06-10.